Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights - PubMed
a day ago
- #ocular complications
- #GLP-1 receptor agonists
- #diabetic retinopathy
- GLP-1 receptor agonists (GLP-1 RAs) are used to treat Type 2 diabetes mellitus (T2DM) and obesity.
- Concerns exist about ocular adverse events linked to GLP-1 RAs, such as nonarteritic anterior ischemic optic neuropathy (NAION).
- Semaglutide, a GLP-1 RA, has been associated with increased risks of NAION and diabetic retinopathy progression.
- Studies show mixed results, with some finding no significant link between GLP-1 RAs and ocular complications.
- Adverse event reporting systems indicate a need for further research into these potential risks.
- Clinicians should be aware of possible ocular hazards and consider closer monitoring for patients with existing eye conditions.
- More prospective research is needed to clarify the correlations and ensure safe use of GLP-1 RAs.